Medtronic submits full data on spinal protein to independent scrutiny
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d5484 (Published 30 August 2011) Cite this as: BMJ 2011;343:d5484- Deborah Cohen
- 1BMJ
The company at the centre of an investigation by a US Senate committee into an alleged failure to mention the side effects of a spinal treatment it makes has agreed to fund an independent review into the safety and effectiveness of the product. It is the first time that a medical technology company has agreed to this type of detailed scrutiny.
Medtronic announced in early August that it will give Yale University $2.5m (£1.5m; €1.7m) to review all published and unpublished data on the safety and effectiveness of Infuse Bone Graft, a recombinant bone morphogenetic protein 2 (rhBMP-2) that is used to stimulate bone growth in spine fusion surgery.
In what the company describes as “unprecedented in the medical industry,” academics will be granted access to full patient data possessed by Medtronic—and not …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.